Neuroprotective strategies for intracerebral hemorrhage: Trials and translation

Stroke

Volumn 41, Issue 10 SUPPL. 1, 2010, Pages

  Kellner, Christopher P ^a   Connolly, E Sander ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

clinical trials; intracerebral hemorrhage; neuroprotection

Indexed keywords

CELECOXIB; CITICOLINE; DEFEROXAMINE; DISUFENTON SODIUM; GAVESTINEL; GLYCEROL; MANNITOL; PIOGLITAZONE; ROSUVASTATIN; SIMVASTATIN; TAUROURSODEOXYCHOLIC ACID; NEUROPROTECTIVE AGENT;

BRAIN HEMORRHAGE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE MODEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; HUMAN; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; CEREBRAL HEMORRHAGE; CLINICAL TRIAL (TOPIC);

CEREBRAL HEMORRHAGE; CLINICAL TRIALS AS TOPIC; HUMANS; NEUROPROTECTIVE AGENTS;

EID: 77957994329     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.597476     Document Type: Conference Paper

References (23)

1. Gomis M, Ois A, Rodríguez-Campello A, Cuadrado-Godia E, Jiménez-Conde J, Subirana I, Dávalos A, Roquer J. Outcome of intrace-rebral haemorrhage patients pre-treated with statins. Eur J Neurol. 2010; 17:443-448.
2. Karki K, Knight RA, Han Y, Yang D, Zhang J, Ledbetter KA, Chopp M, Seyfried DM. Simvastatin and atorvastatin improve neurological outcome after experimental intracerebral hemorrhage. Stroke. 2009;40:3384-3389.
3. Naval NS, Abdelhak TA, Zeballos P, Urrunaga N, Mirski MA, Car-huapoma JR. Prior statin use reduces mortality in intracerebral hemorrhage. Neurocrit Care. 2008;8:6-12.
4. Naval NS, Mirski MA, Carhuapoma JR. Impact of statins on validation of ich mortality prediction models. Neurol Res. 2009;31:425-429.
5. Seyfried D, Han Y, Lu D, Chen J, Bydon A, Chopp M. Improvement in neurological outcome after administration of atorvastatin following experimental intracerebral hemorrhage in rats. J Neurosurg. 2004;101: 104-107.
6. Sacco RL, DeRosa JT, Haley EC, Levin B, Ordronneau P, Phillips SJ, Rundek T, Snipes RG, Thompson JL; GAIN Americas Investigators. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. JAMA. 2001;285: 1719-1728
7. Phase II studies of the glycine antagonist gv150526 in acute stroke: the North American experience. The North American Glycine Antagonist In Neuroprotection (GAIN) investigators. Stroke. 2000;31:358-365.
8. Lees KR, Lavelle JF, Cunha L, Diener HC, Sanders EA, Tack P, Wester P, Group GPIES. Glycine antagonist (gv150526) in acute stroke: a mul-ticentre, double-blind placebo-controlled phase II trial. Cerebrovasc Dis. 2001;11:20-29.
9. Haley EC, Thompson JLP, Levin B, Davis S, Lees KR, Pittman JG, Derosa JT, Ordronneau P, Brown DL, Sacco RL. Gavestinel does not improve outcome after acute intracerebral hemorrhage: an analysis from the GAIN International and GAIN Americas studies. Stroke. 2005;36: 1006-1010.
10. Lyden PD, Shuaib A, Lees KR, Davalos A, Davis SM, Diener H-C, Grotta JC, Ashwood TJ, Hardemark H-G, Svensson HH, Rodichok L, Wasiewski WW, Ahlberg G, Investigators CT. Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT trial. Stroke. 2007;38:2262-2269.
11. Iranmanesh F, Vakilian A. Efficiency of citicoline in increasing muscular strength of patients with nontraumatic cerebral hemorrhage: a double-blind randomized clinical trial. J Stroke Cerebrovasc Dis. 2008; 17:153-155.
12. Secades JJ, Alvarez-Sabin J, Rubio F, Lozano R, Davalos A, Castillo J. Citicoline in intracerebral haemorrhage: a double-blind, randomized, placebo-controlled, multi-centre pilot study. Cerebrovasc Dis. 2006;21: 380-385.
13. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Am J Cardiol. 2001;87:28B-32B.
14. Tapia-Perez H, Sanchez-Aguilar M, Torres-Corzo JG, Rodriguez-Leyva I, Gonzalez-Aguirre D, Gordillo-Moscoso A, Chalita-Williams C. Use of statins for the treatment of spontaneous intracerebral hemorrhage: results of a pilot study. Cen Eur Neurosurg. 2009;70:15-20.
15. Misra UK, Kalita J, Ranjan P, Mandal SK. Mannitol in intracerebral hemorrhage: a randomized controlled study. J Neurol Sci. 2005;234: 41-45.
16. Yu YL, Kumana CR, Lauder IJ, Cheung YK, Chan FL, Kou M, Chang CM, Cheung RT, Fong KY. Treatment of acute cerebral hemorrhage with intravenous glycerol. A double-blind, placebo-controlled, randomized trial. Stroke. 1992;23:967-971.
17. Okauchi M, Hua Y, Keep RF, Morgenstern LB, Xi G. Effects of defer-oxamine on intracerebral hemorrhage-induced brain injury in aged rats. Stroke. 2009;40:1858-1863.
18. Selim M. Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials. Stroke. 2009;40:S90-S91.
19. Park H-K, Lee S-H, Chu K, Roh J-K. Effects of celecoxib on volumes of hematoma and edema in patients with primary intracerebral hemorrhage. J Neurol Sci. 2009;279:43-46.
20. Sinn D-I, Lee S-T, Chu K, Jung K-H, Song E-C, Kim J-M, Park D-K, Kim M, Roh J-K. Combined neuroprotective effects of celecoxib and memantine in experimental intracerebral hemorrhage. Neurosci Lett. 2007;411:238-242. (Pubitemid 44828283)
21. Lee S-R, Kim H-Y, Hong J-S, Baek W-K, Park J-W. PPARgamma agonist pioglitazone reduces matrix metalloproteinase-9 activity and neuronal damage after focal cerebral ischemia. Biochem Biophys Res Commun. 2009;380:17-21.
22. Zhao X, Grotta J, Gonzales N, Aronowski J. Hematoma resolution as a therapeutic target: the role of microglia/macrophages. Stroke. 2009;40: S92-S94.
23. Rodrigues CM, Sola S, Nan Z, Castro RE, Ribeiro PS, Low WC, Steer CJ. Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proc Natl Acad Sci U S A. 2003;100:6087-6092.